Pharmacokinetic/pharmacodynamic (PK/PD) modelling can be used to characterize the
relationship between dose regimen of opioids, plasma concentration and effect of opioids …

Purpose: BupredermTM-Buprenorphine transdermal delivery system (BTDS) was developed
for the treatment of post-operative and chronic pains. This study examined the relationship …

This paper reviews the current clinical data for the role of transdermal buprenorphine (BUP
TDS) in the treatment of diverse acute and chronic pain syndromes. Literature searches …

BACKGROUND AND PURPOSE Chronic pain and hyperalgesia can be difficult to treat with
classical opioids acting predominately at the µ‐opioid receptor. Buprenorphine and its active …

Objective To develop a model to predict buprenorphine plasma concentrations during
transition from transdermal to buccal administration. Design Population pharmacokinetic …

Different mechanisms were proposed for opioid-induced analgesia and antihyperalgesia,
which might result in different pharmacodynamics. To address this issue, the time course of …

Background: Musculoskeletal pathologies are among the most frequent causes of long-term
non-oncological severe pain and consequent physical impairment. Aims of pharmacological …

Buprenorphine is a potent opioid analgesic clinically used to treat moderate to severe pain.
The present study assessed its analgesic efficacy in a broad range of rodent models of acute …

Buprenorphine was not used widely in clinical practice over many years, mainly due to
analgesic potency and clinical safety concerns based on misinterpreted animal data …

BACKGROUND:: Buprenorphine, a potent opioid analgesic, has been available in
parenteral and oral or sublingual (SL) formulations for> 25 years. In 2001, the …